Ionescu, Bentley, Eikermann, Taylor, Akeju, Swee, Pavone, Petrie, Dording, Mischoulon, Alpert, Brown, Baer, Nock, Fava, and Cusin (2018) The purpose of this study is to study the efficacy and longevity of Ketamine’s antidepressant and antisuicidal properties when compared to placebo. Ages 18-65, primary dx: MDD, HDRS ≥ 20, Hx of ≥ 3 failed antidepressant treatment regimes, “distressing” levels of SI >3 mo, but not severe enough to need immediate hospitalization, able to maintain Experimental Pretest-Posttest Random Control Group Design Ketamine-IV Intervention group-DV HDRS - 28-item rating scale that assesses symptoms of depression experienced over the past week scored either on a 3-point or 5-point Likert-type scale Columbia-Suicide Severity Rating Scale (C-SSRS) SI score - captures the presence of Despite previous study results, this study showed that ketamine did NOT outperform placebo in the treatment of depression. Sample: 50% had failed ECT, and the average current MDD episode was almost 10 years. Authors suggest higher doses of ketamine may need to be used to generate a response given
KETAMINE AS AN ADJUNCT TREATMENT FOR DEPRESSION 7 treatment ≥ 4 weeks prior to trial, and able to maintain psychiatrist and chaperone. Not: pregnant, bipolar, psychotic, unstable medical disorder, substance abuse < 1 year, and not on specific medications due to possibility of reaction. suicidal thoughts, as rated on a 5- point ordinal scale this severely and chronically depressed population.
KETAMINE AS AN ADJUNCT TREATMENT FOR DEPRESSION 8 This is a review of recent and relevant studies that show ketamine’s efficacy in alleviating symptoms of major depressive disorder (MDD) and suicidal ideation (SI). The presented articles were discovered by searching “ketamine AND depression” in the Cumulative Index of Nursing and Allied Health (CINAHL), PubMed, and a general web search using Bing. Many more relevant articles were available; however, they were not included due to cost, time constraints, and assignment limitations. MDD is a prevalent and deadly disease. Approximately 34 million Americans alive today will experience MMD within their lifetimes (Kessler et al., 2003). Of those, about 30% will not respond to traditional medication and treatment (Rush et al., 2009). Most traditional antidepressant medications can take two weeks or longer to become effective. Recent studies have shown ketamine to be very effective in alleviating symptoms of MDD and suicidal ideation (SI) in as little as 40 minutes after infusion with results that last up to a week or more (Burger et al., 2016; Ionescu et al., 2018; Kheirabadi, Vafaie, Kheirabadi, Mirlouhi, & Hajiannasab, 2019; Nugent, Wills, Gilbert, & Zarate, 2018). Most studies concentrate on the effects of ketamine alone. However, little evidence exists to show how ketamine can be used as an emergency
- Fall '16
- Denise Cauble